What question did this study set out to answer?

This study aims to determine the long-term prognosis of ER-positive, HER2-negative early breast cancer patients based on responses to neoadjuvant endocrine therapy and the Oncotype DX assay results.

June 19, 2026Breast CancerOpen Access

Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial

View Full Paper

Ask AI

Bookmark

Authors

HIHiroji Iwata NMNorikazu Masuda YYYutaka Yamamoto

Discussion

Member takes

Overview

Randomized trial evaluates outcomes in postmenopausal early breast cancer patients based on treatment responses and multigene assays, suggesting a role for chemotherapy assessment.

Key Points

This study aims to determine the long-term prognosis of ER-positive, HER2-negative early breast cancer patients based on responses to neoadjuvant endocrine therapy and the Oncotype DX assay results.
Phase 3 NEOS trial with 296 registered patients, 226 included in analysis.
Multigene assays categorized into low, intermediate, and high Recurrence Scores.
Kaplan–Meier methods assessed disease-free survival and overall survival based on treatment response.
In the RS low and intermediate groups, no significant difference in disease-free survival or overall survival was found between ET alone and CT + ET.
In the RS high group, overall survival was significantly lower in the ET group compared to CT + ET (p = 0.037).
Among RS high patients achieving clinical responses, no significant overall survival difference was observed between CT + ET and ET alone (p = 0.25).

Cite This Study

Iwata et al. (2026) studied this question.

synapsesocial.com/papers/6a34e06865a5b0777af2f09b https://doi.org/10.1007/s12282-026-01862-3

View Full Paper

Ask AI

Bookmark

June 19, 2026Breast CancerOpen Access

Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial

View Full Paper

Ask AI

Bookmark

Authors

HIHiroji Iwata NMNorikazu Masuda YYYutaka Yamamoto

Discussion

Member takes

Overview

Randomized trial evaluates outcomes in postmenopausal early breast cancer patients based on treatment responses and multigene assays, suggesting a role for chemotherapy assessment.

Key Points

This study aims to determine the long-term prognosis of ER-positive, HER2-negative early breast cancer patients based on responses to neoadjuvant endocrine therapy and the Oncotype DX assay results.
Phase 3 NEOS trial with 296 registered patients, 226 included in analysis.
Multigene assays categorized into low, intermediate, and high Recurrence Scores.
Kaplan–Meier methods assessed disease-free survival and overall survival based on treatment response.
In the RS low and intermediate groups, no significant difference in disease-free survival or overall survival was found between ET alone and CT + ET.
In the RS high group, overall survival was significantly lower in the ET group compared to CT + ET (p = 0.037).
Among RS high patients achieving clinical responses, no significant overall survival difference was observed between CT + ET and ET alone (p = 0.25).

Cite This Study

Iwata et al. (2026) studied this question.

synapsesocial.com/papers/6a34e06865a5b0777af2f09b https://doi.org/10.1007/s12282-026-01862-3

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark